voltadol 140 mg medicinsk plaster
2care4 aps - diclofenacnatrium - medicinsk plaster - 140 mg
voltarol 140 mg medicinsk plaster
haleon denmark aps - diclofenacnatrium - medicinsk plaster - 140 mg
voriconazole "sandoz" 200 mg filmovertrukne tabletter
sandoz a/s - voriconazol - filmovertrukne tabletter - 200 mg
oxis turbohaler 9 mikrogram/dosis inhalationspulver
paranova danmark a/s - formoterolfumarat dihydrat - inhalationspulver - 9 mikrogram/dosis
srivasso 18 mikrogram inhalationspulver, hård kapsel
2care4 aps - tiotropiumbromidmonohydrat - inhalationspulver, hård kapsel - 18 mikrogram
oxis turbuhaler 9 mikrogram/dosis inhalationspulver
abacus medicine a/s - formoterolfumarat dihydrat - inhalationspulver - 9 mikrogram/dosis
imatinib koanaa
koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter, der har en lav eller meget lav risiko for tilbagefald, bør ikke modtage adjuverende behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. undtagen i nyligt diagnosticeret kronisk cml-fase, der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.
padma 28 tabletter
padma europe gmbh - aegle marmelos frugt, pulver, gul potentil, islandsk mos, kaempferia galanga rhizoma, kryddernellike, morgenfrue blomst, myrobalan frugt, paternostertræ, frugt - tabletter
tekcis radionuklidgenerator
cis bio international oris ind. - natriummolybdat (99m-mo) - radionuklidgenerator
epistatus 10 mg mundhulevæske, opløsning
serb s.a. - midazolammaleat - mundhulevæske, opløsning - 10 mg